Related Experiment Video
Updated: Dec 31, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis
Wei Wei1, Ruihao Peng1, Lishan Kuang1
1Department of Health Statistics, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China.
Abstract:
Clinical trials have previously assessed various therapies for renal cell carcinoma (RCC); however, there is currently a lack of direct comparisons between these therapies. The present study identified published studies on RCC through Web of Science, PubMed, EMBASE, Cochrane Library of Controlled Trials and Clinical trials.gov that were written in the English language and published by February 2019. The data were selected and extracted independently by two reviewers. Standard pair-wise meta-analyses were performed using Stata. Network meta-analyses were subsequently performed using WinBUGS (version 1.4.3). The primary outcome of the present study was progression-free survival (PFS). Secondary outcomes included overall survival (OS), objective response rate (ORR) and adverse events of various targeted therapies. The results were presented as cumulative odds ratio, hazard ratio, corresponding 95% confidence interval and the surface under the cumulative ranking curve, which was used to rank the probabilities and outcome of each treatment in RCC. A total of 31 eligible publications for 18 randomized controlled trials consisting of 11,498 participants were included in the present study. The network meta-analyses revealed that a combination of lenvantinib and everolimus ranked first out of 16 treatments in terms of PFS, OS and ORR (probability of 54.0, 53.4 and 61.0%, respectively).
Insights
In renal cell carcinoma (RCC) treatment, lenvatinib plus everolimus showed the best outcomes for progression-free survival, overall survival, and objective response rate in a network meta-analysis. This combination therapy offers a promising option for patients with advanced kidney cancer.
Area of Science:
- Oncology
- Clinical Pharmacology
- Biostatistics
Background:
- Numerous therapies exist for renal cell carcinoma (RCC), but direct comparative data are limited.
- Evaluating the comparative efficacy of targeted therapies in RCC is crucial for treatment selection.
Purpose of the Study:
- To conduct a network meta-analysis comparing various targeted therapies for renal cell carcinoma (RCC).
- To identify the optimal treatment strategy based on progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).
Main Methods:
- Systematic literature search across major databases (PubMed, EMBASE, Web of Science, etc.) for eligible randomized controlled trials (RCTs) published by February 2019.
- Inclusion of 31 publications from 18 RCTs involving 11,498 participants.
- Application of standard pair-wise and network meta-analyses using Stata and WinBUGS.
Main Results:
- The combination of lenvatinib and everolimus demonstrated superior efficacy across multiple endpoints.
- This combination ranked highest for progression-free survival (PFS) with a 54.0% probability.
- It also showed the highest probability for overall survival (OS) at 53.4% and objective response rate (ORR) at 61.0% among 16 evaluated treatments.
Conclusions:
- Lenvatinib plus everolimus combination therapy emerges as the leading treatment option for renal cell carcinoma (RCC) based on current evidence.
- This finding provides valuable guidance for clinicians in selecting the most effective targeted therapy for RCC patients.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Cancer Survival Analysis